Scientific Reports
February 25, 2026
Albert Garcia‐romeu, Gideon P. Naudé, Alison W. Rebman et al.
2 citations
Abstract Lyme disease, caused by the bacterium Borrelia burgdorferi , is the most common vector-borne disease in the United States and Europe. Although antibiotics effectively treat most cases, an estimated 10–20% of patients develop post-treatment Lyme disease (PTLD), a chronic syndrome marked by fatigue, pain, cognitive difficulties, mood disturbance, and reduced quality of life. There are no...
Frontiers in Psychiatry
September 19, 2023
Hillary Jackson, Sara So, Abigail Yaffe et al.
87 citations
Introduction The classic psychedelic psilocybin, found in some mushroom species, has received renewed interest in clinical research, showing potential mental health benefits in preliminary trials. Naturalistic use of psilocybin outside of research settings has increased in recent years, though data on the public health impact of such use remain limited. Methods This prospective, longitudinal...
Journal of Psychopharmacology
January 9, 2021
Alan K. Davis, Frederick S. Barrett, Sara So et al.
166 citations
Background: Several measures have been developed to examine acute psychedelic effects (e.g. mystical-type and challenging experiences), but no measure assesses acute psychologically insightful experiences that may occur during psychedelic experiences. Aim: The purpose of this study was to develop and examine the psychometric properties of the Psychological Insight Questionnaire. Method: A...
The American Journal of Drug and Alcohol Abuse
2019
Alan K. Davis, Sara So, Rafael Lancelotta et al.
141 citations
A recent epidemiological study suggested that 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used for spiritual and recreational reasons is associated with subjective improvement in depression and anxiety. Further exploration of the potential psychotherapeutic effects of 5-MeO-DMT could inform future clinical trials. We examined self-reported improvement in depression and anxiety among people who...